Karolinska Development AB

Equities

KDEV

SE0002190926

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm Other stock markets 17:00:01 17/07/2024 BST			5-day change	1st Jan Change
1.456 ^SEK	-8.66%		+1.53%	-14.25%

07-10	Umecrine Cognition AB announced that it has received SEK 28.3 million in funding from Ribbskottet AB, AB Ility AB, Karolinska Development AB and other investors	CI
05-28	Karolinska Development Targets 10% Stake in Boost Pharma	MT

Karolinska Development AB, KDev Oncology AB, Aprea AB and Akinion Pharmaceuticals AB Announce Executive Changes

January 29, 2015 at 08:22 am

Karolinska Development AB announced that the company's CEO Bruno Lucidi leaves the company. He is replaced by Deputy CEO Terje Kalland until a new, permanent CEO is appointed. The recruitment process for a permanent CEO has been initiated.

At the same time, Bruno Lucidi also leaves his roles as CEO for KDev Oncology AB and Karolinska Development's portfolio companies Aprea AB and Akinion Pharmaceuticals AB. Karolinska Development's Deputy CEO Terje Kalland is appointed Acting CEO until a new, permanent CEO is appointed.

Latest news about Karolinska Development AB

Umecrine Cognition AB announced that it has received SEK 28.3 million in funding from Ribbskottet AB, AB Ility AB, Karolinska Development AB and other investors	07-09	CI
Karolinska Development Targets 10% Stake in Boost Pharma	05-28	MT
Boost Pharma Aps announced that it expects to receive funding from Industrifonden, Karolinska Development AB	05-27	CI
Karolinska Development AB Appoints Hans Wigzell as Director and as Chairman	05-16	CI
Karolinska Development AB Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
Karolinska Development AB Announces That Björn Cochlovius Has Declined Re-Election	04-16	CI
Karolinska Development AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-16	CI
Karolinska Development Portfolio Company AnaCardio Completes SEK150 Million Funding Round	01-17	MT
AnaCardio AB announced that it has received SEK 150 million in funding from Industrifonden, Karolinska Development AB, Flerie Invest AB	01-16	CI
Karolinska Development Takes Part in Portfolio Company Umecrine Cognition's Capital Raise	11-17	MT
Karolinska Development AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-17	CI
Umecrine Cognition AB announced that it has received SEK 30.4 million in funding from Karolinska Development AB, Ribbskottet AB, Ab Ility Ab and other investors	11-16	CI
Modus Therapeutics to Launch SEK40 Million Rights Offering, Issue Shares to Offset SEK20 Million Loan	11-08	MT
Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal Surgery	19/09/23	CI
Karolinska Development AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	25/08/23	CI
Karolinska Unit's Investigational Drug Shows Potential as Anemia Treatment	12/05/23	MT
Karolinska Development AB Reports Earnings Results for the First Quarter Ended March 31, 2023	28/04/23	CI
Karolinska Development's Portfolio Company Biosergen Presents Positive Results from Phase 1 Study of Drug Candidate to Treat Systemic Fungal Infection	13/03/23	CI
Karolinska Development AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	17/02/23	CI
Karolinska Development AB Reports Earnings Results for the Full Year Ended December 31, 2022	17/02/23	CI
Karolinska Development AB Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive Data	14/02/23	CI
Karolinska Development Up 9% as Umecrine Wins US Orphan Drug Tag for Liver Disease Drug Candidate	17/01/23	MT
Karolinska Development AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	18/11/22	CI
Karolinska Development Partakes In Danish Dermatology Company Henlez' Seed Financing	24/10/22	MT
Henlez Aps announced that it has received €1 million in funding from Karolinska Development AB, Eir Ventures	23/10/22	CI

Chart Karolinska Development AB

Duration

Period

More charts

Company Profile

Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, womenâs health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Companyâs pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.

Sector

Medical Equipment, Supplies & Distribution

Calendar

30/08/2024 - Q2 2024 Earnings Release

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
KAROLINSKA DEVELOPMENT AB	-14.25%	40.5M
ABBOTT LABORATORIES	-4.90%	179B
MEDTRONIC PLC	-1.36%	100B
DEXCOM, INC.	-7.64%	46.16B
HOYA CORPORATION	+11.46%	44.81B
CENCORA, INC.	+9.63%	44.38B
METTLER-TOLEDO INTERNATIONAL, INC.	+13.63%	29.53B
TERUMO CORPORATION	+20.32%	25.83B
WEST PHARMACEUTICAL SERVICES, INC.	-7.12%	23.97B
STERIS PLC	+4.03%	22.5B

Other Medical Equipment, Supplies & Distribution